CG Oncology, Inc Common stock

Yahoo Finance • 24 days ago

As Terns Stock Soars 1,400%, What Does One Fund's $5.2 Million Sale Signal to Investors?

On February 17, 2026, Acorn Capital Advisors reported selling 225,000 shares of Terns Pharmaceuticals(NASDAQ:TERN), an estimated $5.20 million trade based on quarterly average pricing. What happened According to a filing with the Securit... Full story

Yahoo Finance • 26 days ago

This Biotech Stock Up 135% Just Faced a $44 Million Trim. Here's What Investors Should Know

Kynam Capital Management reduced its position in CG Oncology(NASDAQ:CGON), selling 1,059,375 shares in the fourth quarter for an estimated $43.84 million based on quarterly average pricing, according to a February 17, 2026, SEC filing. Wh... Full story

Yahoo Finance • last month

H.C. Wainwright Raises its Price Target on CG Oncology, Inc. (CGON) to $80 and Maintains a Buy Rating

CG Oncology, Inc. (NASDAQ:CGON) is among the 10 Fastest Growing NASDAQ Stocks to Buy.H.C. Wainwright Raises its Price Target on CG Oncology, Inc. (CGON) to $80 and Maintains a Buy Rating On February 27, 2026, H.C. Wainwright raised the fi... Full story

Yahoo Finance • 2 months ago

CG Oncology GAAP EPS of -$2.08 beats by $0.09, revenue of $4.04M beats by $1.24M

* CG Oncology press release [https://seekingalpha.com/pr/20417455-cg-oncology-reports-2025-year-end-financial-results-and-provides-business-updates] (CGON [https://seekingalpha.com/symbol/CGON]): FY GAAP EPS of -$2.08 beats by $0.09. *... Full story

Yahoo Finance • 4 months ago

Here are the most and least likely M&A targets in biotech, according to Truist

[M&A - concept waiting for mergers and acquisitions.3D rendering on yellow background.] French biotech (ABVX [https://seekingalpha.com/symbol/ABVX]) has emerged as the most likely acquisition target among biotechs in 2026, significantly o... Full story

Yahoo Finance • 4 months ago

New Cretostimogene Grenadenorepvec Data Highlight its Potential to Become the Backbone Therapy for High-Risk Non-Muscle Invasive Bladder Cancer

Cretostimogene demonstrated HG-EFS at 3- 6- and 9-months of 95.7%, 84.6% and 80.4%, respectively, in HR BCG UR Ta/T1 Disease in BOND-003 Cohort P CORE-008 Cohort A Data in HR BCG-Naïve NMIBC demonstrates 88% CR and favorable safety with op... Full story

Yahoo Finance • 5 months ago

CG Oncology Announces New Board Member and Board Transition

- Appoints Accomplished Life Sciences Executive Christina Rossi to its Board of Directors - IRVINE, Calif., Nov. 26, 2025 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ: CGON), a late-stage clinical biopharmaceutical company focused on d... Full story

Yahoo Finance • 5 months ago

CG Oncology Reports Third Quarter 2025 Financial Results and Provides Business Updates

Initiated rolling Biologics License Application (BLA) submission to U.S. FDA for cretostimogene monotherapy in high-risk (HR) BCG-unresponsive non-muscle invasive bladder cancer (NMIBC)Demonstrated continued best-in-disease durability and... Full story

Yahoo Finance • 6 months ago

Noteworthy Tuesday Option Activity: CGON, DECK, ARQT

Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in CG Oncology Inc (Symbol: CGON), where a total of 4,018 contracts have traded so far, representing approximately 401,800 underlying... Full story

Yahoo Finance • 6 months ago

ClearBridge Small Cap Strategy adds KWR, RNA, exits SEAT, GDRX among Q3 moves

The ClearBridge Small Cap Strategy underperformed its Russell 2000 Index benchmark during the third quarter, despite registering gains in 10 of the 11 sectors in which it was invested during the quarter. ClearBridge Small Cap Strategy, in... Full story

Yahoo Finance • 6 months ago

CG Oncology jumps as Guggenheim starts at Buy on potential against bladder cancer

[Business on Wall Street in Manhattan] Pgiam/iStock via Getty Images CG Oncology (NASDAQ:CGON [https://seekingalpha.com/symbol/CGON]), a biotech focused on non-muscle invasive bladder cancer (NMIBC), traded ~9% higher on Wednesday after G... Full story

Yahoo Finance • 7 months ago

CG Oncology Continues to Demonstrate Best-in-Disease Durability and Tolerability in BOND-003 Cohort C; Additional 12 Patients in Complete Response at 24 Months

- Robust 24-month complete response (CR) rate of 41.8% observed for cretostimogene monotherapy in patients with high-risk non-muscle invasive bladder cancer (NMIBC) who are unresponsive to Bacillus Calmette Guerin (BCG) treatment - - 90%... Full story

Yahoo Finance • 7 months ago

CG Oncology Completes Enrollment in PIVOT-006

– Rapid enrollment underscores high unmet need in intermediate-risk non-muscle invasive bladder cancer (NMIBC) – – One of the largest randomized phase 3 studies in this patient population will encompass broadest range of patient types per... Full story

Yahoo Finance • 8 months ago

CG Oncology’s Executive Leadership to Participate in Upcoming Investor Conferences

IRVINE, Calif., Aug. 29, 2025 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ: CGON), a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients w... Full story

Yahoo Finance • 8 months ago

Piper Sandler initiates CG Oncology stock coverage with Overweight rating

Investing.com - Piper Sandler initiated coverage on CG Oncology (NASDAQ:CGON) with an Overweight rating and a price target of $55.00 on Tuesday. The company, currently valued at $1.96 billion, trades at $26.13, with analyst targets rangi... Full story

Yahoo Finance • 8 months ago

CG Oncology GAAP EPS of -$0.54

* CG Oncology press release [https://seekingalpha.com/pr/20194834-cg-oncology-reports-second-quarter-2025-financial-results-and-provides-business-updates] (NASDAQ:CGON [https://seekingalpha.com/symbol/CGON]): GAAP EPS of -$0.54. * Cash... Full story

Yahoo Finance • 8 months ago

CG Oncology Reports Second Quarter 2025 Financial Results and Provides Business Updates

- Announced best-in-disease durability data in BOND-003 Cohort C and promising early signal in Cohort P for cretostimogene grenadenorepvec at the American Urological Association Annual Meeting - - Initiated CORE-008 Cohort CX evaluating t... Full story

Yahoo Finance • 9 months ago

Precision Genetic Medicine Platform Could Disrupt Standard of Care in Metastatic Cancer, Other Indications of Unmet Needs

NetworkNewsWire Editorial Coverage NEW YORK, July 7, 2025 /CNW/ -- An estimated 20 million people are diagnosed annually with cancer, while cancer kills almost 10 million people a year worldwide (https://ibn.fm/dyQrw) with these numbers e... Full story

Yahoo Finance • 10 months ago

CG Oncology to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference

IRVINE, Calif., June 05, 2025 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ: CGON), a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients w... Full story

Yahoo Finance • 11 months ago

CG Oncology Reports First Quarter 2025 Financial Results and Provides Business Updates

- Updated BOND-003 clinical results presented at AUA showing best-in-disease durability and tolerability data for Cohort C with 24-month complete response rate of 42.3% by K-M - - Promising early signal in Cohort P with 90.5% high-grade r... Full story